97964-72-2

Upstream product

• 103882-09-3 N-Boc-4-I-Phe-OH 
• 868694-44-4 [(1S)-1-carbamoyl-2-(4-iodophenyl)ethyl]carbamic acid tert-butyl ester 
• 1991-81-7 4-iodo-L-phenylalanine 
• 63-91-2 L-phenylalanine 

Downstream Products

• 1161498-12-9 (S)-tert-butyl 2-((S)-1-amino-3-(4-iodophenyl)-1-oxopropan-2-yl carbamoyl)piperidine-1-carboxylate 
• 1254318-91-6 (S)-tert-butyl-4-(1-amino-3-(4-iodophenyl)-1-oxopropan-2-yl carbamoyl)tetrahydro-2H-pyran-4-yl carbamate 
• 1254318-84-7 (S)-4-amino-N-(1-cyano-2-(4-(2-methyl-3-oxoisoindolin-5-yl)phenyl)ethyl)tetrahydro-2H-pyran-4-carboxamide trifluoroacetic acid salt 
• 1254319-24-8 (S)-tert-butyl-4-(1-amino-1-oxo-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-2-yl carbamoyl)tetrahydro-2H-pyran-4-yl carbamate 
• 1254319-52-2 (S)-tert-butyl-4-(1-amino-3-(4-(2-methyl-3-oxoisoindolin-5-yl)phenyl)-1-oxopropan-2-yl carbamoyl)tetrahydro-2H-pyran-4-yl carbamate 
• 1428666-14-1 (1R, 3S, 4S)-tert-butyl 3-((S)-1-amino-3-(4-iodophenyl)-1-oxopropan-2-ylcarbamoyl)-2-azabicyclo[2.2.1]heptane-2-carboxylate 
• 1428666-97-0 C₂₆H₃₉N₅O₄ 
• 1352152-85-2 (S)-tert-butyl 1-(1-amino-3-(4-iodophenyl)-1-oxopropan-2-ylcarbamoyl)cycloheptylcarbamate 
• 1352152-82-9 (S)-4'-(3-amino-2-(1-(tert-butoxycarboxamido)cyclohexanecarbonylamino)-3-oxopropyl)biphenyl-4-yl methanesulfonate 
• 1352152-78-3 (S)-1-amino-N-(1-cyano-2-(4-(1-(2-methoxyethyl)-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)cyclohexanecarboxamide trifluoroacetate 
• 1352152-80-7 (S)-tert-butyl 1-(1-cyano-2-(4-(1-(2-methoxyethyl)-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethylcarbamoyl)cyclohexylcarbamate 
• 1352152-79-4 (S)-tert-butyl 1-(1-amino-3-(4-(1-(2-methoxyethyl)-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-1-oxopropan-2-ylcarbamoyl)cyclohexylcarbamate 
• 1352152-75-0 (S)-4'-(2-(1-aminocyclohexanecarboxamido)-2-cyanoethyl)-3-fluorobiphenyl-4-carboxamide trifluoroacetate 
• 1352152-76-1 (S)-tert-butyl 1-(2-(4'-carbamoyl-3'-fluorobiphenyl-4-yl)-1-cyanoethylcarbamoyl)cyclohexylcarbamate 

Relevant academic research and scientific papers

SUBSTITUTED N- [1-CYANO-2- (PHENYL) ETHYL] -2-AZABICYCLO [2.2.1] HEPTANE-3-CARBOXAMIDE INHIBITORS OF CATHEPSIN C

Disclosed are N-1-cyano-2-(phenyl)ethyl)-2-azabicyclo[2.2.1]heptane-3-carboxamides of formula I and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of respiratory diseases.

SUBSTITUTED N- [1-CYANO-2- (PHENYL) ETHYL] -2-AZABICYCLO [2.2.1] HEPTANE-3-CARBOXAMIDE INHIBITORS OF CATHEPSIN C

This invention relates to N-1-cyano-2-(phenyl)ethyl)-2-azabicyclo[2.2.1]heptane-3-carboxamides of formula I, and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of respiratory diseases.

SUBSTITUTED N-[1-CYANO-2-(PHENYL)ETHYL] 1-AMINOCYCLOALK-1-YLCARBOXAMIDE COMPOUNDS - 760

The present invention provides compounds of formula (I) in which, n, R1, R2 and Q are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.

SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750

The present invention provides compounds of formula (I), in which y, m, n, R1, R2 and Q are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.

SUBSTITUTED N-[1-CYANO-2-(PHENYL)ETHYL]PIPERIDIN-2-YLCARBOXMIDE COMPOUNDS 761

The present invention provides a compound: (S)-N-((S)-1-Cyano-2-(4-(1-methyl-2-oxoindolin-6-yl)phenyl)ethyl)piperidine-2- carboxamide; (S)-N-((S)-1-Cyano-2-(4-(3-(3-methoxypropyl)-2-oxo-2,3-dihydrobenzo[d]oxazol-5- yl)phenyl)ethyl)piperidine-2-carboxamide; (S)-N-((S)-1-Cyano-2-(4'-(ethylsulfonyl)biphenyl-4-yl)ethyl)piperidine-2-carboxamide; 4'-((S)-2-Cyano-2-((S)-piperidine-2-carboxamido)ethyl)biphenyl-4-yl methanesulfonate; or, (S)-N-((S)-1-Cyano-2-(4-(1-oxoisoindolin-5-yl)phenyl)ethyl)piperidine-2-carboxamide; or a pharmaceutically acceptable salt thereof; a process for its preparation, pharmaceutical compositions containing it and its use in therapy.

PEPTIDYL NITRILES AND USE THEREOF AS DIPEPTIDYL PEPTIDASE I INHIBITORS

The present invention provides compounds of formula (I) in which n, y, X1, X2, A, B, R1, R2, R3, R4 and R5 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use as dipeptidyl peptidase I (DPPI) inhibitors.

METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

Metal control of non-polar binding shape selectivity

Ligand 1 forms a hydrophobic cavity upon binding to metals, the shape of which depends on the metal. A reversal in binding preference for naphthalene or biphenyl groups is found when the metal is changed from zinc to copper, with a selectivity change of 260 fold.

Synthesis of a new ligand for metal assembly to a selective receptor

Diarylphosphinic acid 2, bearing two ethylenediamine groups, was designed with the aim of assembly to form a hydrophobic cavity upon binding to metals. The new ligand was prepared in optically active form from phenylalanine by an efficient sequence which required chromatography only for the P-C bond forming steps. Versatile intermediates in the synthesis are described. Complexes of this ligand with Zn2+ were shown to bind closely related aromatic guests bearing anionic tethered groups with 1000-fold discrimination. Diarylphosphinic acid 2, bearing two ethylenediamine groups, was designed with the aim of assembly to form a hydrophobic cavity upon binding to metals. The new ligand was prepared in optically active form from phenylalanine by an efficient sequence which required chromatography only for the P-C bond forming steps. Versatile intermediates in the synthesis are described. Complexes of this ligand with Zn2+ were shown to bind closely related aromatic guests bearing anionic tethered groups with 1000-fold discrimination.